Novartis

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

1 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Health & Biotech 04 Oct 2026, 08:22 AM IST

Novartis Agrees to Up to $7.8 Billion mRNA Deal With China’s Abogen

Novartis has struck a licensing and development agreement with Chinese biotech Abogen Biosciences that could be worth as much as $7.8 billion, underscoring the Swiss drugmaker’s push into next-generation cancer therapies. The deal centers on an mRNA-encoded T-cell engager, a highly targeted approach that has drawn intense interest from large pharmaceutical companies seeking to replenish pipelines and deepen exposure to innovative Chinese science.

By RDU Global Wire6 min read

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Novartis:

China(1)Abogen Biosciences(1)